

hESC derivation

Anna Veiga^{1,2}, Begoña Aran¹

1.-Centre de Medicina Regenerativa de Barcelona

2.-Institut Universitari Dexeus. Barcelona

Pluripotency

Embryonic Stem Cells

Methodology for hESC derivation

- Embryo culture. Embryo quality
- ICM isolation
- hESC derivation and culture conditions
 - Feeder cells
 - Xeno-free, feeder free and GMP derivation
- Results

Pluripotency

Developmental potential

Totipotent
Zygote

Pluripotent
ICM/ES cells, EG cells,
EC cells, mGS cells
iPS cells

Multipotent
Adult stem cells
(partially reprogrammed cells?)

Unipotent
Differentiated cell types


Epigenetic status

Global DNA demethylation


Only active X chromosomes;
Global repression of differentiation genes by Polycomb proteins;
Promoter hypomethylation

X inactivation;
Repression of lineage-specific genes by Polycomb proteins;
Promoter hypermethylation

X inactivation;
Derepression of Polycomb silenced lineage genes;
Promoter hypermethylation



Hochedlinger, Development 2009 (adapted from Waddington, 1957)



Van de Velde, 2009

The four blastomeres of a 4-cell stage human embryo are able to develop individually into blastocysts with inner cell mass and trophectoderm

❄ **Pluripotent** Stem Cells can be obtained from cells located in the inner cell mass of blastocysts and from nuclear reprogramming (SCNT and iPS).

Embryonic Stem cells

ESSAY

30 years: from IVF to stem cells


Ruth Deech, former chair of Britain's Human Fertilisation and Embryology Authority, reflects on how the science that gave an infertile couple a baby has been extended to saving lives.



The Nobel Prize in Physiology or Medicine 2010
Robert G. Edwards


Embryonic Stem Cells

- ❄ Derived from the **inner cell mass** of the blastocyst (**ICM**) (day 5-7 of development, \pm 150-200 cells). They give rise to the 3 germ layers: ectoderm, mesoderm and endoderm.



Timelapsegroup Rigshospital Copenhagen and Brødstrup Hospital, Denmark

Embryonic Stem Cells: Self Renewal and Differentiation



Embryonic stem cells

Embryo origin

- IVF embryos donated for research.
PGD/PGS abnormal embryos
- Embryos created for research from donated gametes
- Embryos created through somatic cell nuclear transfer (SCNT)
- Other possibilities: parthenogenesis,...

Methodology for hESC derivation

- Embryo culture. Embryo quality

Establishment in culture of pluripotential cells from mouse embryos

M. J. Evans* & M. H. Kaufman†

Letters to Nature

Nature **292**, 154-156; 1981




Embryonic Stem Cell Lines Derived from Human Blastocysts

James A. Thomson, *et al.*

Science **282**, 1145 (1998);

DOI: 10.1126/science.282.5391.1145




Methodology

- Embryo thawing and culture to the blastocyst stage.
- Zona pellucida removal
- ICM isolation (optional)
- Seeding

Methodology

- Embryo thawing* or warming*.
- Embryo culture*.


Embryos at different developmental stages (day 1, day 2 , day 3) have to be cultured to the blastocyst stage.




* Protocols developed at the IVF laboratory to be followed

Blastocyst classification


- Expansion degree
- Number of cells of the ICM
- Number of cells and trophectoderm appearance




good



intermediate



poor




Proposal for a universal minimum information convention for the reporting on the derivation of human embryonic stem cell lines.

Emma Stephenson^{1,2}, Peter Braude^{2,3}, Chris Mason¹

Future Medicine, Reg. Medicine
1(6), 739-750; 2006

Derivation, Characterization, and Differentiation
of Human Embryonic Stem Cells

NICO HEINS,^{a*} MIKAEL C.O. ENGLUND,^{a*} CECILIA SJÖBLOM,^{a*} ULF DAHL,^b ANNA TONNING,^b
CHRISTINA BERGH,^c ANDERS LINDAHL,^d CHARLES HANSON,^e HENRIK SEMB^b




2003

Derivation of Embryonic Stem-Cell Lines
from Human Blastocysts

2004


Chad A. Cowan, Ph.D., Irina Klimanskaya, Ph.D., Jill McMahon, M.S., Jocelyn Atienza, B.S.,
Jeannine Witmyer, Ph.D., Jacob P. Zucker, B.S., Shunping Wang, Ph.D., Cynthia C. Morton, Ph.D.,
Andrew P. McMahon, Ph.D., Doug Powers, Ph.D., and Douglas A. Melton, Ph.D.



Derivation of Human Embryonic Stem Cells from Day-8
Blastocysts Recovered after Three-Step In Vitro Culture

MIODRAG STOJKOVIC,^a MAJLINDA LAKO,^a PETRA STOJKOVIC,^a REBECCA STEWART,^b
STEFAN PRZYBORSKI,^b LYLE ARMSTRONG,^b JERRY EVANS,^a MARY HERBERT,^c LOUISE HYSLOP,^a
SAJJAD AHMAD,^a ALISON MURDOCH,^c TOM STRACHAN^a

2004



Optimal Timing of Inner Cell Mass Isolation Increases the Efficiency of Human Embryonic Stem Cell Derivation and Allows Generation of Sibling Cell Lines









Alice E. Chen,^{4,8} Dieter Egli,^{4,8} Kathy Niakan,⁴ Jie Deng,⁷ Hidenori Akutsu,⁸ Mariko Yamaki,⁴ Chad Cowan,^{1,2,6} Claire Fitz-Gerald,⁴ Kun Zhang,⁷ Douglas A. Melton,^{2,2,4,9} and Kevin Eggan^{1,2,4,9}

Table 1. Derivation is Most Efficient on Day 6 Postfertilization

Day of ICM Isolation	Number of Blastocysts Used for Derivation	Number of Attachment Sites (Percent of Blastocysts)	Number of ICM Outgrowths	Number of Cell Lines	Percent Derivation Efficiency
5	19	6 (31)	1	1	5
6	27	22 (81)	15	14	52 ^a
7	27	22 (81)	9	9	33
8	19	17 (90)	5	5	26
9	11	10 (91)	4	4	36
No isolation	10	10 (100)	1	1	10
Unknown ^b	27	ND	ND	11	40


Embryo quality and derivation efficiency

- Discarded embryos; *Mitalipova, 2003*
- Poor quality blastocysts; *Cowan, 2004*
- Day 3 low score embryos; *Chen 2005*
- Arrested embryos; *Zhang, 2007;Feki 2008*
- Poor quality embryos; *Lerou, 2008*
- Poor quality blastocysts; *Raya, 2008*
- Poor quality blastocysts; *Aran, 2010*



Methodology

Zona pellucida removal



- Pronase: xenobiotic, less aggressive
- Acid Tyrode's: xenofree, more aggressive


Methodology for hESC derivation

- ICM isolation

Methodology

ICM isolation (optional)

- Immunosurgery
- Laser dissection
- Mechanical dissection




Methodology

Immunosurgery


Use of antibodies (antihuman and complement) in order to lyse the cells of the trophoblast

Solter and Knowles, 1975



Methodology

Laser dissection



Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: applications and preliminary results in a murine model

Noriko Tanaka¹, Takumi Takeuchi¹, Queenie V Neri¹, Eric Scott Sills² and Gianpiero D Palermo^{*1}

2006

Evaluation of a laser technique to isolate the inner cell mass of murine blastocysts

José Luis Cortés^{*1}, Fernando Cobo^{*}, Purificación Catalina^{*}, Ana Nieto^{*}, Carmen Cabrera^{*}, Rosa Montes^{*}, Ángel Concha[†] and Pablo Menendez^{*1}

2007

Laser-assisted derivation of human embryonic stem cell lines from IVF embryos after preimplantation genetic diagnosis

T. Turetsky^{1,†}, E. Aizenman^{2,*}, Y. Gil¹, N. Weinberg³, Y. Shufaro^{1,2}, A. Revel², N. Laufer², A. Simon², D. Abeliovich³ and B.E. Reubinoff^{1,2,4}

2008

Methodology

Mechanical dissection

Human Reproduction Vol.22, No.12 pp. 3051–3058, 2007
Advance Access publication on October 24, 2007

doi:10.1093/humrep/dem335

Mechanical isolation of the inner cell mass is effective in derivation of new human embryonic stem cell lines

Susanne Ström^{1,†}, José Inzunza^{2,†}, Karl-Henrik Grinnemo³, Kerstin Holmberg⁴,
Eija Matilainen¹, Anne-Marie Strömberg¹, Elisabeth Blennow⁴ and Outi Hovatta^{1,5}


2007

Flexible metal needles (0.125 mm diameter) used to open the ZP and dissect the ICM

Methodology

Alternatives to the ICM isolation and seeding

- *Whole blastocysts*
Heins, 2003
- *Morula*
Strelchenko, 2004;
Tesar, 2005
- *Single blastomeres*
Klimanskaya, 2006
Chung, 2007



Methodology

Embryo seeding – hESC culture

- ICMs or ZP free blastocysts are transferred to feeder dishes.
- hESC culture medium: Knockout DMEM with 2nmol/ml Glutamax, 0.05 mmol/l 2-mercaptoethanol, 8 ng/ml bFGF, 1% non essential aminoacids, 20% knockout SR and 0.5% penicillin-streptomycin.

Methodology

Feeder cells

- Unknown mechanisms that control the undifferentiated proliferation of hESC
- Feeder cells must produce factors associated with cell surface adherence and are responsible for the maintenance of the undifferentiated phenotype of the hESC


Methodology for hESC derivation

- hESC derivation and culture conditions
 - Feeder cells

Methodology

Feeder cells

- Mouse embryonic fibroblasts
Thomson, 1998
- Human foreskin fibroblasts
Hovatta, 2003
- Human placental fibroblasts
Genbacev, 2005



Methodology for hESC derivation

- hESC derivation and culture conditions
 - Xeno-free, feeder free and GMP derivation

Methodology

Alternative matrices

Proteic matrix of complex composition

- Matrigel; *Xu, 2001*
- Mouse embryonic fibroblast extracellular matrix, *Klimanskaya, 2005*

Proteic matrix of defined composition

- Laminin; *Xu, 2001; Li 2005*
- Collagen IV, laminin, fibronectin and vitronectin; *Ludwig, 2006*

© Human embryonic stem cells derived without feeder cells ©

Lancet 2005; 365: 1401-08 | Xia Zhou, Young Chang, Lorraine Akle, Jeff Johnson, Michael O'West, Robert Lanza

2005

Derivation of human embryonic stem cells in defined conditions

2006

Tenneille E Ludwig^{1, 2, 3}, Mark E Levenstein¹, Jeffrey M Jones^{1, 4}, W Travis Berggren¹, Erika R Mitchen¹, Jennifer L Frane^{2, 3}, Leann J Crandall¹, Christine A Daigh^{2, 3}, Kevin R Conard¹, Marian S Piekarczyk¹, Rachel A Llanas¹ & James A Thomson^{1, 2, 3, 4, 5}

Report of derivation and culture of feeder free hESC with protein components derived from recombinant sources or purified human material

Derivation of a Xeno-Free Human Embryonic Stem Cell Line

2006

CATHARINA ELLERSTRÖM,^{a,b} RAIMUND STREHL,^b KARINA MOYA,^b KATARINA ANDERSSON,^a CHRISTINA BERGH,^c KERSTI LUDIN,^c JOHAN HYLLNER,^b HENRIK SENI^b

Report of the establishment and characterisation of a hESC without animal origin components


Testing of nine different xeno-free culture media for human embryonic stem cell cultures

2007

Kristiina Rajala^{1,4}, Heidi Hakala¹, Sarita Panula¹, Suvi Aivio¹, Harri Pihlajamäki², Riitta Suuronen¹, Outi Hovatta^{1,3} and Heli Skottman¹

Test reagent

Control hESC medium



Human serum

Lipumin™ 10×

Plasmanate

SerEx 10×




Serum substitute supplement (SSS)

SR3


TeSR1

X-Vivo 10

X-Vivo 20



The Generation of Six Clinical-Grade Human Embryonic Stem Cell Lines



Crook et al, 2007

hESC culture

Isolation and culture conditions **without animal origin** products and **defined conditions** are needed to envisage therapeutic approaches (GMP conditions)

Results

Banc de Linies Cel.lulars de Barcelona

Results

Results of embryo thawing and hESC derivation (1st series)

1st series	2PN zygotes	cleavage stage embryos	blastocysts	total
embryos thawed	20	35	6	61
embryos surviving (%)	10 (50%)	28 (80%)	4 (66.7%)	42 (68.8%)
blastocysts (%)	3 (30%)	10 (35.7%)		
blastocysts/ICM seeded	3	10	4	17
outgrowths	-	3	2	5
hESC lines	0	3 (30%)	2 (50%)	5 (29.4%)

Banc de Linies Cel.lulars de Barcelona

Results

Results of embryo thawing and hESC derivation (2nd series)

2nd series	cleavage stage embryos
embryos thawed	66
embryos surviving (%)	58 (87.8%)
blastocysts (%)	13 (22.4%)
blastocysts/ICM seeded	11
outgrowths	1
hESC lines	1 (9.1%)

Banc de Linies Cel.lulars de Barcelona

Results

Results of embryo thawing and hESC derivation (3rd series)

3rd series	cleavage stage embryos
embryos thawed	62
embryos surviving (%)	15 (24.2%)
blastocysts (%)	4 (26.7%)
blastocysts/ICM seeded	5
outgrowths	3
hESC lines	3 (60%)

Banc de Linies Cel.lulars de Barcelona

Results

Results of embryo thawing and hESC derivation from abnormal embryos (PGD)

	Aneuploidies	Monogenic diseases	Total
Thawed blastocysts	67	19	86
Survival blastocysts	44 (65.7%)	14 (73.7%)	58 (68.1%)
Blastocysts/ICM seeded	33	9	42
Lines	-	1	1 (2.4%)

Autor	Year	Lab.	embryos	ICM (n)	Cell lines	Effic. (%) [*]
Thomson ⁴	1998	WiCell, USA	36	14	H1,H7,H9, H13,H14	36
Reubinoff ³¹	2000	Monash Inst. Austr./Singapore	N/A	2	HES-1, HES2	?
Lanzendorf ²⁹	2001	Jones Inst for Reprod. Med., USA	110	18	ES-76, ES-78-1, ES-78-2	17
Amit ⁴⁰	2002	Rambam Med. Center, Israel	5	5	I-3, I-4, I-6	60
Richards ⁵⁰	2002	Dept. Obs. Gyn. NU Singapore	1	1	1	?
Hovatta ³²	2003	Karolinska Inst. Sweden	N/A	2	HS181, HS207	?
Mitalipova ²⁶	2003	BresaGen, USA	19	8	BG01, BG02, BG03, BG04	50
Park ⁵¹	2003	MizMedi Hosp Seoul, Korea	N/A	13	3	23
Pickering ³⁸	2003	Guy's, King's & St Thomas Med. UK	58	N/A	3	?
Baharvand ²⁷	2004	Royan Inst, Iran	N/A	1	Royan H11	?
Heins ⁵²	2004	Cellartis AB, Sweden	N/A	N/A	SA002,FC018 AS034,AS038 SA121 SA181(abn)	N/A
Cowan ³³	2004	Howard Hughes Medical Inst, USA	286 clev.+ 58 blasts	97	HUES1-17	18
Park ⁵³	2004	Maria Infertility Hospital, Korea	20blastos 20Pron.	11 3	MB01-07 MB08-09	64 67
Sjögren ²⁰	2004	Goteborg Univ., Sweden	748	114	22	19
Stojkovic ²⁴	2004	Univ. Newcastle, UK	11 day-2 embryos	7	HES-NCL1	14
Strelchenko ⁴³	2004	Repr. Genetic Inst Chicago, USA	46			
			morula,	11	8	17
			39 blast.	12	7	18
			32 ICM	5	5	16
Suss-Toby ³⁴	2004	Rambam Medical Center, Israel	60	6	19	17
Verlinsky ³⁵	2005	RGI Chicago, USA	72	N/A	18 abn	N/A
Chen ²⁵	2005	Tongi Hosp., China	130	10	2	20

Veiga, 2007

Author	Year	Lab.	embryos	ICM (n)	Cell lines	Effic. (%) [*]
<i>Findikli</i> ²¹	2005	Istambul Mem. Hosp., Turkey	31	N/A	7	N/A
<i>Genbacev</i> ¹³	2005	UCSF, USA	192 321	14 10	UCSF-2 UCSF-1	7 10
<i>Inzunza</i> ⁴²	2005	Karolinska Inst., Sweden	10	N/A	HS293, HS206	N/A
<i>Kim HS</i> ³⁹	2005	Seoul Nat. Univ., Korea	N/A	N/A	13	N/A
<i>Kim SJ</i> ⁵⁴	2005	MizMedi Hosp. Korea	N/A	16	Miz-Hes4-8, 10-13	56
<i>Klimanskaya</i> ¹²	2005	ACT, USA	N/A	5	ACT-14	20
<i>Lee</i> ⁵⁵	2005	MRC MizMedi Hosp. Korea	8 PN-stage	7	Miz-endol,-2,-3	43
<i>Li</i> ⁵⁶	2005	Hosp. Sun Yat-sen Univ., China	N/A	4	CHES-1	25
<i>Lysdahl</i> ⁵⁷	2006	Aalborg Univ., Denmark	198	23	CLS1, CLS2, CLS3, CLS4	17
<i>Mummery</i> ³⁷	2005	Hubrecht Lab., The Netherlands	22	N/A	NL-HESC1	N/A
<i>Oh</i> ⁵⁸	2005	MRC, Seoul Nat Univ., Korea	73	10	SNUhES1-3	30
<i>Pickering</i> ⁴⁶	2005	Guy's, King's & St Thomas Med. UK	N/A	N/A	CF1 abn	N/A
<i>Simon</i> ³⁶	2005	Valecia Stem Cell Bank	40	16	VAL-1, VAL-2	13
<i>Wang</i> ⁵⁹	2005	Xiinhua Hospital, China	N/A	N/A	SH1, SH2, SH7	N/A
<i>Baharvand</i> ⁴⁸	2006	Royan Inst, Iran	N/A	N/A	Royan H2-3-4-5-6 (abn)	N/A
<i>Hampfl</i>	2006	Acad. Sci. Czech Republic	98	14	CCTL8,9,6,10, 12,14	42
<i>Mardal</i> ⁶⁰	2006	Reliance Life Sciences, India	N/A	N/A	ReliCell@hES1	N/A
<i>Mateizel</i> ⁴⁷	2006	Res. C. Reprod. Genetics, Belgium	69	52	VUB1,2, 3,4,5 (abn)	10
<i>Ludwig</i> ¹⁵	2006	WiCell	N/A	N/A	WA15, WA16	N/A

Veiga, 2007

Autor	Fresh/ Frozen embryos	Feeders	ICM Isolation	culture (d) before ICM isolation	initial split* (Mec. Coll. Disp)
<i>Thomson</i> ⁴	Fresh/ frozen	Irrad MEF	Immuno	N/A	
<i>Reubinoff</i> ³¹	Frozen	MitoC MEF	Immuno	6	MD
<i>Lanzendorf</i> ²⁹	Fresh	Irrad MEF	Immuno	6	M4-11
<i>Amit</i> ⁴⁰	Frozen	MEF	Immuno	N/A	
<i>Richards</i> ⁵⁰	Frozen	MitoC HF (FetMusl)	Immuno	N/A	MD 10
<i>Hovatta</i> ³²	Fresh	Irrad postnatHFF	Immuno	6	D9-19
<i>Mitalipova</i> ²⁶	Frozen	Irrad MEF	Immuno	6_7	M7-10
<i>Park</i> ⁵¹	Frozen	MitoC MEF	Immuno		
<i>Pickering</i> ³⁸	N/A	N/A	N/A	N/A	N/A
<i>Baharvand</i> ²⁷	N/A	MitoC MEF	No Immuno	6	M1
<i>Heins</i> ⁵²	Fresh/ Frozen	MitoC MEF	Immuno	6_7	M7
<i>Cowan</i> ³³	Frozen	MitoC MEF	Immuno	N/A	M
<i>Park</i> ⁵³	Frozen	MitoC STO	Immuno	N/A	M5-8
<i>Sjögren</i> ²⁰	Fresh/ Frozen	MEF	Immuno	6_8	
<i>Stojkovic</i> ²⁴	Fresh	Irrad MEF	Immuno	8	M17
<i>Strelchenko</i> ⁴³	N/A	MitoC MEF or BRL	Immuno	N/A	
<i>Suss-Toby</i> ³⁴	Fresh	Inact MEF	No Immuno	N/A	M
<i>Verlinsky</i> ³⁵	Fresh PGD	MitoC MEF or BRL			ED8-14
<i>Chen</i> ²⁵	Fresh	MitoC MEF	Immuno	5_8	M5-8


Veiga, 2007

Author	Fresh/ Frozen embryos	Feeders	ICM Isolation	culture (d) before ICM isolation	Initial split* (Mec. Coll. Disp)
<i>Findikli</i> ²¹	Fresh	MitoC MEF	15Immuno, 12 direct	5-7	7-10
<i>Genbacev</i> ¹³	Frozen Fresh	Human Placental fibroblasts	No Immuno	N/A	M
<i>Inzunza</i> ⁴²	3frozen, 7fresh	Irrad HFF	Immuno	6	M12
<i>Kim HS</i> ³⁹	Frozen	MitoC STO	Immuno/Mechanical	N/A	M7
<i>Kim SJ</i> ⁵⁴	Frozen	MitoC MEF	Immuno	N/A	M
<i>Klimanskaya</i> ¹²	Frozen	MitoC Lysed MEFs	Immuno	N/A	
<i>Lee</i> ⁵⁵	Frozen	MitoC Human endometrial	Immuno	N/A	M6-8
<i>Li</i> ⁵⁶	Frozen	Irrad MEF	Immuno	N/A	
<i>Lysdahl</i> ⁵⁷	Fresh	Irrad HFF	Immuno	N/A	M10-15
<i>Mummery</i> ³⁷	Fresh	MitoC MEF	Immuno	N/A	MD8
<i>Oh</i> ⁵⁸	Frozen	MitoC STO	Immuno/ whole	5-7	M7-8
<i>Pickering</i> ⁴⁶	Fresh PGD	N/A	N/A	N/A	M17
<i>Simon</i> ³⁶	Frozen	Human Placental	No Immuno	N/A	M15 M21
<i>Wang</i> ⁵⁹	N/A	Irrad MEF 55Gy EDF	Immuno	N/A	M/C 10-14
<i>Baharvand</i> ⁴⁸	N/A	MitoC MEF	Immuno	5,5	MD 10
<i>HAMPL</i>	Frozen	MEF	Immuno	N/A	N/A
<i>Marda</i> ⁶⁰	N/A	N/A	N/A	N/A	N/A
<i>Mateizel</i> ⁴⁷	Frozen/ Fresh	Irrad/MitoC MEF	Immuno	N/A	N/A
<i>Ludwig</i> ¹⁵	Frozen	N/A	Immuno	N/A	N/A


Veiga, 2007

Parthenogenetic ES cells
from human oocytes

Fertilization



Parthenogenesis





Activation:

Ionomycin: flux of intracellular Ca^{++} → reactivation of meiosis




6-DMAP: block the 2nd PB extrusion → 2n embryo


Culture:

G1/G2 medium for human IVF embryos up to blast (D+5/7)




Oocytes	1PN1PB @ 18h	Cleaved @ D2	Blastocysts @ D5	Cell lines
17	12	16 (94%)	6 (37.5%)	1 (6.25%)










DNA
Nanog
TRA 1-81



DNA
Oct4
SSEA3



DNA
Sox2
SSEA4
Tra 1-60




Welcome

Quicksearch

- Home
- Detailed Search
- Show available Cell Lines
- Show all Research Projects
- Show all Provider
- My hESCreg
- Login
- Register
- About hESCreg
- Project Structure
- EU hESC Research
- Legislation
- Ethics
- Newsletter
- Contact

Welcome



Register:
[Cell Line](#)
[Research Project](#)

Login to my hESCreg

Show:
[Available Cell Lines](#)
[All Research Projects](#)
[All Research Provider](#)



Welcome to the European Human Embryonic Stem Cell Registry – hESCreg

You have entered the work-in-progress site of the hESCreg database. Here you can browse the database or log in using the Username/Password combination issued to you. At the first login we advise you to change your personal Username/Password combination to one only known to yourself. If you are a provider of hES cell lines we are calling on you to complete the minimum registration information for your pre-registered cell lines. If there are any new lines please add them as well. We would greatly appreciate if you could complete this by the end of November 2007. Apart from that we are looking forward to receiving your comments or suggestions. Should you have any problems operating the database or would like to contribute to the further development of the database please direct all communication to helpdesk@hescreg.eu.

Until the official launch of hESCreg on January 18, 2008, in Berlin the interim web page at www.hescreg.eu will act as the official information resource of the initiative.

Thank you very much in advance for your contributions!



aveiga@cmrb.eu

anavei@dexeus.com



Banc de Línies
Cel.lulars.

Centre de Medicina Regenerativa de Barcelona